{
    "abstract": "Hepatoblastoma is a rare pediatric liver malignancy usually treated with surgery and chemotherapy. To explore new treatment options for hepatoblastoma, drug screening was performed using six cell models established from aggressive hepatoblastoma tumors and healthy pediatric primary hepatocytes. Of the 527 screened compounds, 98 demonstrated cancer-selective activity in at least one hepatoblastoma model. The kinesin spindle protein (KSP) inhibitor filanesib was effective in all models and was further evaluated. Filanesib induced G2/M arrest and apoptosis in hepatoblastoma cells at concentrations tolerable to primary hepatocytes. Prominent nuclear fragmentation was observed in filanesib-treated hepatoblastoma cells. Genes participating in cell cycle regulation were noted to be differentially expressed after filanesib treatment. Filanesib reduced the rate of tumor growth in 4/5 hepatoblastoma mice models. One of these models showed complete growth arrest. Our results suggest that filanesib is a potential candidate for hepatoblastoma treatment and should be investigated in future clinical trials.",
    "authors": [
        {
            "affiliation": "Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.\nInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.",
            "firstname": "Ruth",
            "initials": "R",
            "lastname": "Nousiainen"
        },
        {
            "affiliation": "Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. katja.eloranta@helsinki.fi.\nInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland. katja.eloranta@helsinki.fi.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland. katja.eloranta@helsinki.fi.",
            "firstname": "Katja",
            "initials": "K",
            "lastname": "Eloranta"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.",
            "firstname": "Jani",
            "initials": "J",
            "lastname": "Saarela"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.",
            "firstname": "Antti",
            "initials": "A",
            "lastname": "Hassinen"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.",
            "firstname": "Tamara J",
            "initials": "TJ",
            "lastname": "Luck"
        },
        {
            "affiliation": "XenTech, Evry, France.\nChampions Oncology, Hackensack, NJ, USA.\nIstituto di Ricerca Pediatrica, Padova, Italy.",
            "firstname": "Stefano",
            "initials": "S",
            "lastname": "Cairo"
        },
        {
            "affiliation": "XenTech, Evry, France.",
            "firstname": "Emilie",
            "initials": "E",
            "lastname": "Indersie"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.",
            "firstname": "Swapnil",
            "initials": "S",
            "lastname": "Potdar"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.",
            "firstname": "Michaela J",
            "initials": "MJ",
            "lastname": "Feodoroff"
        },
        {
            "affiliation": "Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.",
            "firstname": "Jouko",
            "initials": "J",
            "lastname": "Lohi"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.",
            "firstname": "Lassi",
            "initials": "L",
            "lastname": "Paavolainen"
        },
        {
            "affiliation": "Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA.\nDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.",
            "firstname": "David B",
            "initials": "DB",
            "lastname": "Wilson"
        },
        {
            "affiliation": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.\niCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.",
            "firstname": "Vilja",
            "initials": "V",
            "lastname": "Pieti\u00e4inen"
        },
        {
            "affiliation": "Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.\nDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.\nFaculty of Medicine and Health Technology, Center for Child, Adolescent, and Maternal Health Research, Tampere University, Tampere, Finland.",
            "firstname": "Markku",
            "initials": "M",
            "lastname": "Heikinheimo"
        },
        {
            "affiliation": "Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.",
            "firstname": "Marjut",
            "initials": "M",
            "lastname": "Pihlajoki"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2025. The Author(s).",
    "doi": "10.1038/s41698-025-00915-8",
    "journal": "NPJ precision oncology",
    "keywords": [],
    "methods": null,
    "publication_date": "2025-04-26",
    "pubmed_id": "40281281\n31651371\n18074355\n15390302\n16126064\n17962810\n11219776\n29190888\n18975283\n27884679\n37962078\n29924955\n12056699\n29489754\n25135868\n34456337\n39567475\n31741706\n10838414\n24898935\n26771021\n33125945\n36934951\n22613880\n31761183\n30002710\n32962010\n37302584\n38242326\n20651736\n36336065\n29247830\n30488605\n37073741\n27904761\n35251692\n1406972\n8227131\n32961118\n34378481\n37656243\n15808464\n22522457\n37894278\n33652084\n28561052\n22153075\n34921527\n28817190\n22139909\n32501528\n25684345\n32967973\n20712019\n32119072\n37996540\n1710634\n23085117\n27560178\n29969450\n30531897\n37377594\n21999641\n25751142\n25260700",
    "results": null,
    "title": "Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.",
    "xml": "<Element 'PubmedArticle' at 0x788506890b80>"
}